A 3-month Randomized, Double-Blind, Placebo-Controlled, Feasibility Study to Evaluate the Effects of MSDC-0160 on Brain Glucose Utilization, Cognition, Safety and Tolerability in Older Persons With Mild Alzheimer's Disease.

Trial Profile

A 3-month Randomized, Double-Blind, Placebo-Controlled, Feasibility Study to Evaluate the Effects of MSDC-0160 on Brain Glucose Utilization, Cognition, Safety and Tolerability in Older Persons With Mild Alzheimer's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs MSDC 0160 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Sponsors Metabolic Solutions Development Company
  • Most Recent Events

    • 09 Sep 2013 Results will be presented at the 14th International Conference on Alzheimer's Drug Discovery according to a Metabolic Solutions Development Company media release. Results were also briefly summarised in the media release.
    • 30 Nov 2012 Planned End Date changed from 1 Dec 2012 to 1 May 2013, as reported by ClinicalTrials.gov.
    • 30 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top